Allergic diseases diagnosis and treatment
2025 Activity Indicators
- 3 competitive national public projects: ISCIII
- 2 private projects led
- 15 clinical studies
- 1 competitive HR contract
- 32 publications
- IF: 189.60
- Publications in Q1: 24 (75%)
- Publications in D1: 20 (63%)
- 5 doctoral theses supervised and defended
- 1 award
- Evaluators for medical agencies and societies: 6 researchers
- Members of editorial boards: 5 researchers
- 11 students hosted and 30-month stays: Polytechnic University of Madrid; University Hospital of La Princesa, Madrid; University Hospital of Donosti; University Hospital of São João (Portugal) & Chile General Hospital (Chile)
Milestones
- Inclusion of the Environmental Exposure Chamber (EEC) as a scientific and technical device of interest for research on the EATRIS platform. Inclusion of the EEC as a research device in a project funded by AES 2025, for the study of respiratory allergy to oak pollen (PI25/00453).
- Clinical advances and application of big data analytics and artificial intelligence technology to the study of adverse reactions to monoclonal drugs used in different pathologies (cancer, rheumatology, hematology, and internal medicine), with AES 2025 funding: PI25/01189.
- Leadership of the multicenter project CLARA (Clinical, Asthma, Response, and Air): multidisciplinary, AstraZeneca Foundation ISCIII.
- Creation of a digital platform for planning highly complex procedures in collaboration with the UPM (INGENIA Project) with databases and their exploitation for research.
- Publication of the Super RCA molecular flow cytometry technique, to detect clonality in peripheral blood in mastocytosis, as an alternative improvement to diagnosis by bone marrow biopsy.
Bibliometrics
| Articles | Accum. FI | Mean FI | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
|---|---|---|---|---|---|---|---|
| 2021 | 17 | 93.25 | 5.49 | 15 | 88 | 2 | 12 |
| 2022 | 12 | 88.70 | 9.86 | 8 | 66,67 | 1 | 8,33 |
| 2023 | 36 | 237.52 | 7.20 | 32 | 89 | 5 | 14 |
| 2024 | 19 | 105.70 | 5.87 | 18 | 95 | 2 | 11 |
| 2025 | 32 | 189.60 | 6.32 | 30 | 94 | 20 | 63 |
| 116 | 714.77 | 6.95 | 103 | 86 | 30 | 21 |
* Only original articles, editorials, guidelines and reviews